EUCTR2013-004728-13-DE进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 710
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Have a diagnosis of HR+, HER2- breast cancer
- •Have locally advanced disease not amenable to curative treatment by surgery or metastatic disease. In addition, participants must fulfill 1 of
- •the following criteria:
- •- relapsed with radiologic evidence of progression while receiving
- •neoadjuvant or adjuvant endocrine therapy, with no subsequent
- •endocrine therapy received following progression
- •- relapsed with radiologic evidence of progression within 1 year from
- •completion of adjuvant endocrine therapy, with no subsequent endocrine
- •therapy received following progression
- •- relapsed with radiologic evidence of progression more than 1 year from
- •completion of adjuvant endocrine therapy and then subsequently
- •relapsed with radiologic evidence of progression after receiving
- •treatment with either an antiestrogen or an aromatase inhibitor as
- •endocrine therapy for metastatic disease. Patients may not have
- •received more than 1 line of endocrine therapy or any prior
- •chemotherapy for metastatic disease
- •- presented de novo with metastatic disease and then relapsed with
- •evidence of progression after receiving treatment with either an
- •antiestrogen or an aromatase inhibitor as first-line endocrine therapy for
- •metastatic disease. Patients may not have received more than 1 line of
- •endocrine therapy or any prior chemotherapy for metastatic disease
- •Have postmenopausal status due to either surgical/natural menopause or ovarian suppression (initiated at least 28 days prior to Day 1 of Cycle 1) with a gonadotropin-releasing hormone (GnRH) agonist such as goserelin
- •Have a negative serum pregnancy test at baseline (within 14 days prior to randomization) and agree to use medically approved precautions to prevent pregnancy during the study and for 12 weeks following the last dose of abemaciclib if postmenopausal status is due to ovarian suppression with a GnRH agonist
- •Have either measurable disease or nonmeasurable bone only disease
- •Have a performance status =1 on the ECOG scale
- •Have discontinued previous therapies for cancer (including specifically, aromatase inhibitors, anti-estrogens, chemotherapy, radiotherapy, and immunotherapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (until the toxicity resolves to either baseline or at least Grade 1) except for residual alopecia or peripheral neuropathy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 426
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 284
排除标准
- •Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study
- •Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis visceral crisis is not the mere presence of visceral metastases but implies severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of the disease
- •Have clinical evidence or history of central nervous system metastasis
- •Have received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor
- •Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days prior to randomization of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively
- •Have received recent (within 28 days prior to randomization) yellow fever vaccination
- •Have had major surgery within 14 days prior to randomization of study drug to allow for post-operative healing of the surgical wound and site(s)
- •Have a personal history within the last 12 months of any of the
- •following conditions: syncope of cardiovascular etiology, ventricular
- •tachycardia, ventricular fibrillation, or sudden cardiac arrest
- •Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest
- •Have inflammatory breast cancer or a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years
- •Have received an autologous or allogeneic stem-cell transplant
- •Have active bacterial or fungal infection, or detectable viral infection
- •Have initiated bisphosphonates or approved RANK ligand (RANK-L)
- •targeted agents (for example, denosumab) <7 days prior to
- •randomization
研究者
相似试验
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitisMedDRA version: 20.0 Level: PT Classification code 10072579 Term: Granulomatosis with polyangiitis System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: PT Classification code 10063344 Term: Microscopic polyangiitis System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.1 Level: PT Classification code 10050894 Term: Anti-neutrophil cytoplasmic antibody positive vasculitis System Organ Class: 10021428 - Immune system disordersEUCTR2016-001121-14-CZChemoCentryx, Inc.300
进行中（未招募）
1 期
A study to determinate the safety and efficacy of LY3471851 in Adult Patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2019-003323-38-HUEli Lilly & Company280
进行中（未招募）
1 期
irogacestat for Adults With Desmoid Tumor/Aggressive FibromatosisDesmoid Tumors/Aggressive FibromatosisMedDRA version: 20.0Level: LLTClassification code 10059353Term: Desmoid tumorSystem Organ Class: 100000004864EUCTR2018-001991-39-DESpringWorks Therapeutics135
进行中（未招募）
1 期
A Study of Nonsteroidal Aromatase Inhibitors Plus LY2835219 or Placebo in Postmenopausal Women With Breast CancerHormone Receptor Positive, HER2 negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in This Disease SettingMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001502-18-SEEli Lilly and Company450
进行中（未招募）
1 期
A study to assess the efficacy and safety of KRN23 in adults with X-linked Hypophosphatemia (XLH)EUCTR2014-005529-11-IEltragenyx Pharmaceutical Inc.134